Вы и ваши гормоны. Наука о женском здоровье и гормональной контрацепции

216. Cheslack-Postava, K., Keyes, K. M., Lowe, S. R., & Koenen, K. C. (2015). Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Archives of Women’s Mental Health, 18(1), 103–111. doi:10.1007/­s00737-014-0453-4; Lopez, L., Kaptein, A., & Helmerhorst, F. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews. doi:10.1002/­1465­1858.­cd00­6586.

217. Oinonen, K. A., & Mazmanian, D. (2002). To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders, 70(3), 229–240. doi:10.1016/­s0165-0327­(01)­00356-1.

218. Apter, D., Borsos, A., Baumgärtner, W. et al. (2003). Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. European Journal of Contraception and Reproductive Health Care, 8(1), 37–51. doi:10.1080/­7136­04397; Chiou, C., Trussell, J., Reyes, E. et al. (2003). Economic analysis of contraceptives for women. Contraception, 68(1), 3–10. doi:10.1016/­s0010-7824­(03)­00078-7; Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (2001). Concurrent use of oral contraceptives with antidepressants for premenstrual syndromes. Journal of Clinical Psychopharmacology, 21(5), 540–542. doi:10.1097/00004714-200110000-00018; Schultz-Zehden, B., & Boschitsch, E. (2006). User experience with an oral contraceptive containing ethinylestradiol 30μg 30and drospirenone 3mg (Yasmin®) in clinical practice. Treatments in Endocrinology, 5(4), 251–256. doi:10.2165/­0002­4677-2006­05040-00006; Short, M. (2009). User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 μg (Yasminelle®) in clinical practice. Clinical Drug Investigation, 29(3), 153–159. doi:10.2165/­0004­4011-2009­29­030-00002.

219. Lopez, L., Kaptein, A., & Helmerhorst, F. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews. doi:10.1002/­1465­1858.­cd00­6586. Cheslack-Postava, K., Keyes, K. M., Lowe, S. R., & Koenen, K. C. (2015). Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Archives of Women’s Mental Health, 18(1), 103–111. doi:10.1007/­s00737-014-0453-4.

220. Kurshan, N., & Epperson, C. N. (2006). Oral contraceptives and mood in women with and without premenstrual dysphoria: A theoretical model. Archives of Women’s Mental Health, 9(1), 1–14. doi:10.1007/­s00737-005-0102-z; Genazzani, A. R., Stomati, M., Morittu, A.et al. (2000). Progesterone, progestagens and the central nervous system. Human Reproduction, 15(Suppl. 1), 14–27. doi:10.1093/­humrep/­15.suppl_­1.14; Rapkin, A., Morgan, M., Goldman, L. et al. (1997). Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstetrics and Gynecology, 90(5), 709–714. doi:10.1016/­s0029-7844­(97)­00417-1; Sundström, I., Andersson, A., Nyberg, S. et al. (1998). Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology, 67(2), 126–138. doi:10.1159/­000­054­307.